Trial Profile
An Open-Label Safety Study of Pimavanserin in Parkinson's Disease Patients
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 25 Nov 2020
Price :
$35
*
At a glance
- Drugs Pimavanserin (Primary)
- Indications Parkinson's disease; Psychotic disorders
- Focus Adverse reactions
- Sponsors Acadia Pharmaceuticals
- 20 Apr 2017 New trial record